Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing smooth commercialization progress, with significant potential for its pipeline in overseas markets [5] - The company's revenue for the first half of 2025 reached 376 million yuan, representing a year-on-year growth of 56.07%, driven by the inclusion of its product in the national medical insurance directory [7] - The company's key product, Jikaxitini, was successfully approved for market launch in May 2025 and is recommended as a first-line treatment for primary myelofibrosis [7] - The pipeline shows promising potential, with several products advancing through clinical trials and expected to contribute to future revenue growth [7] Financial Summary - Revenue projections for 2025-2027 are estimated at 824 million yuan, 1.388 billion yuan, and 2.391 billion yuan respectively, with year-on-year growth rates of 54.68%, 68.36%, and 72.28% [6][8] - The company is expected to achieve a net profit of 117 million yuan in 2026 and 561 million yuan in 2027, with significant growth rates of 222.86% and 379.53% respectively [6][8] - The current stock price corresponds to a price-to-earnings ratio (P/E) of 242 for 2026 and 50.44 for 2027 [6][8]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

9月1日，泽璟制药涨5.32%，截至发稿，报107.44元/股，成交2.09亿元，换手率0.74%，总市值284.40亿 元。 截至发稿，李涛累计任职时间1年251天，现任基金资产总规模2924.58万元，任职期间最佳基金回报 12.22%， 任职期间最差基金回报11.08%。 资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 数据显示，中国路博迈基金旗下1只基金重仓泽璟制药。路博迈中国医疗健康股票发起A（020142）二 季度持有股数9900股，占基金净值比例为3.64%，位居第十大重仓股。根据测算，今日浮盈赚取约5.38 万元。 路博迈中国医疗健康股票发起A（02014 ...

Group 1: Company Highlights - Mindray Medical launched the world's first clinically implemented critical care AI model and established an animal healthcare subsidiary [1] - Jieshun Technology's cloud-managed SaaS service increased to 16,600 lanes, with software and cloud service revenue reaching 125 million yuan, a year-on-year growth of 26.11% [1] - State Grid Information Technology reported a revenue of 3.525 billion yuan, a decrease of 4.55% year-on-year, while its virtual power plant business is being applied in multiple cities [2] - Inke Recycling focuses on high-value applications of recycled plastics, with significant growth in non-European markets and a projected dividend of 1.00 yuan per 10 shares [3] - ZaiJing Pharmaceutical achieved a revenue of 376 million yuan, a 56% increase, driven by sales growth of its drugs [4] - Tianzhihang reported a revenue of approximately 125 million yuan, a year-on-year increase of 114.89%, with significant growth in orthopedic surgical robot sales [5] - Aibo Medical's revenue reached 787 million yuan, a 14.72% increase, with a gross margin of 65.25% [6] - Mankalon's strategy focuses on expanding its presence in core urban areas and enhancing profitability of franchise stores [7] - Oulu Tong's revenue reached 2.12 billion yuan, a 32.59% increase, with data center power business revenue growing by 94.30% [8] - Sun Paper's special paper project is operational, with plans for further production capacity expansion [9] - Taili Technology is enhancing its market penetration and focusing on customized material solutions for various industries [10] Group 2: Financial Performance - Jieshun Technology's parking asset operation revenue grew by 49.86%, with new orders totaling 677 million yuan [1] - State Grid Information Technology's net profit decreased by 11.01% due to increased corporate income tax [2] - Inke Recycling's non-U.S. market revenue grew by 31.15% year-on-year [3] - ZaiJing Pharmaceutical's new drug approvals are expected to boost future sales [4] - Tianzhihang's orthopedic robot surgeries exceeded 22,000 cases, indicating strong market demand [5] - Aibo Medical's second-quarter revenue was 430 million yuan, a 14.44% increase year-on-year [6] - Oulu Tong's R&D expenses increased by 28.26%, reflecting investment in innovation [8] - Sun Paper's projects are expected to enhance its competitive position in the market [9]

Group 1: Company Highlights - Mindray Medical has launched the world's first clinically implemented critical care large model, named Qiyuan Critical Care Model, and established a subsidiary for animal healthcare [1] - In the field of medical imaging, Mindray's "Ruiying Cloud++" has partnered with DeepSeek to officially release the "Ruiying·AI+" solution [1] - Zai Lab achieved a revenue of 376 million yuan in the first half of 2025, representing a year-on-year growth of 56%, driven by increased drug sales [1] - Zai Lab's recombinant human thrombin has been included in medical insurance, boosting sales, and the company is advancing multiple clinical trials for various tumors [1] - Zai Lab's NDA for Jikaxitini tablets for severe alopecia has been accepted, and several Phase III trials in the autoimmune field are under observation [1] - Dia Group reported a revenue of 786 million yuan in the first half of 2025, a year-on-year increase of 0.97%, with a net profit of 76 million yuan, up 131.61% [2] - The average sales of upgraded stores in the red gold theme have increased by approximately 36% year-on-year [2] - Dia Group plans to implement an equity incentive plan annually over four years and is expanding its presence in overseas markets, particularly in Paris and the U.S. [2] Group 2: Institutional Overview - Tongxin Investment, established in January 2014, is a distinctive sunshine private equity firm with a registered capital of 10 million yuan [3] - The firm is recognized for being one of the few sunshine private equity firms founded by top analysts from New Fortune and has a strong focus on consumer investment [3]

Group 1: Company Highlights - Luxshare Precision's smart glasses are a significant product line in its consumer electronics business, including AI glasses, AR/VR/XR glasses, smart wristbands, and smartwatches [1] - Mindray Medical has launched the world's first clinically implemented critical care AI model, named Qiyuan, and has established a subsidiary for animal healthcare [2] - Jucheng Co. has seen a 110% year-on-year increase in AI glasses shipments, and is one of the only two domestic suppliers to major memory manufacturers, with significant technological accumulation [3] - Zai Jian Pharmaceutical achieved a revenue of 376 million yuan in the first half of 2025, a 56% increase year-on-year, driven by drug sales growth [4] - Fudan Microelectronics is focusing resources on frontline business units to enhance growth potential and strengthen supply chain construction [5] Group 2: Financial Performance and Growth - Jucheng Co. has reported rapid growth in sales and revenue, with its automotive-grade EEPROM products being adopted by several global Tier 1 manufacturers [3] - Zai Jian Pharmaceutical's sales have increased due to the inclusion of recombinant human thrombin in medical insurance, and it is advancing multiple clinical trials for various cancer treatments [4] - Fudan Microelectronics' revenue from security and identification chips reached 393 million yuan, accounting for 21% of total revenue, while its smart card business has declined [5]

Index Performance - The CSI A500 Index increased by 3.34% this week, marking four consecutive weeks of gains, closing at 5372.76 points on August 29 [4][5] - The average daily trading volume for the week was 10,436.75 billion yuan, with a week-on-week increase of 30.39% [4][5] Component Stock Performance - The top ten gainers this week included Tianfu Communication (61.54%), Yanshan Technology (34.86%), and Shenzhen South Circuit (32.07%) [3] - The top ten losers included Berteli (-11.09%), Giant Star Technology (-9.33%), and Weining Health (-7.78%) [3] Fund Performance - All 39 CSI A500 funds reported positive returns, with the highest increase from Guolian An at 4.72% [5] - The total scale of CSI A500 funds reached 1884.32 billion yuan, showing an increase compared to the previous week [5] - The top three funds by scale were Huatai-PB (210.84 billion yuan), E Fund (198.54 billion yuan), and Guotai Fund (195.83 billion yuan) [5] Market Outlook - Current market conditions support continued stock market growth, with reasonable valuations and emerging positive factors such as a potential interest rate cut cycle by the Federal Reserve [6] - The market is expected to experience a "rotation and rebound" characteristic, with short-term rebound opportunities being more noteworthy [7] - In September, basic factors may have a weaker impact on the market, but liquidity-driven trading is at historical highs, suggesting a potential shift in market dynamics [7]

证券代码：688266 证券简称：泽璟制药 公告编号：2025-034 一、药品基本情况 | 药品名称 | 注射用 ZG005 | | 注射用 ZGGS18 | | --- | --- | --- | --- | | 剂型 | 粉针剂 | | 粉针剂 | | 编号 | | IND 177998 | | | 适应症 | | 晚期实体瘤 | | 二、药品相关情况 （1）注射用 ZG005 苏州泽璟生物制药股份有限公司 关于自愿披露注射用 ZG005 与注射用 ZGGS18 联用 的临床试验申请获得 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，苏州泽璟生物制药股份有限公司（以下简称"公司"）在研产品注射 用 ZG005 与注射用 ZGGS18 联用的临床试验申请获得美国食品药品监督管理局 （以下简称"FDA"）批准，用于治疗晚期实体瘤。 本次临床试验获批事项对公司近期业绩不会产生重大影响。由于药品的研发 周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，敬请广 大投资者 ...

Core Viewpoint - ZaiJing Pharmaceutical (688266.SH) announced the approval of its clinical trial application for the combination of injectable ZG005 and ZGGS18 by the U.S. Food and Drug Administration for the treatment of advanced solid tumors [1] Group 1 - Injectable ZG005 is expected to be used for the treatment of various solid tumors and is one of the first drugs globally to enter clinical research for the same target [1] - Currently, there are no similar mechanism drugs approved for marketing worldwide [1] - Injectable ZGGS18 is anticipated to become an innovative biological product for the treatment of solid tumors [1] Group 2 - The approval of this clinical trial will not have a significant impact on the company's recent performance [1]

Core Viewpoint - Zai Jian Pharmaceutical experienced a 5.01% decline in stock price, reaching 97.36 CNY per share, with a total market capitalization of 25.772 billion CNY as of August 28 [1] Company Overview - Suzhou Zai Jian Biopharmaceutical Co., Ltd. was established on March 18, 2009, and went public on January 23, 2020. The company focuses on the research, development, production, and sales of chemical and biological new drugs [1] - The main revenue composition of the company is 99.97% from pharmaceuticals, 0.02% from pharmaceutical intermediates and raw materials, and 0.00% from asset leasing [1] Fund Holdings - Huaxi Fund has a significant holding in Zai Jian Pharmaceutical, with the Huaxi Research Selected Mixed Fund (020444) holding 62,100 shares, accounting for 5.72% of the fund's net value, ranking as the tenth largest holding [2] - The fund has reported a floating loss of approximately 319,100 CNY as of the latest update [2] - The Huaxi Research Selected Mixed Fund was established on December 28, 2023, with a current size of 117 million CNY and has achieved a year-to-date return of 22.25%, ranking 3067 out of 8191 in its category [2] - Over the past year, the fund has generated a return of 53.02%, ranking 2083 out of 7967 in its category, and has an overall return of 18.01% since inception [2] - The fund manager, Wu Wenqing, has a tenure of 11 years and 249 days, with the best fund return during his tenure being 96.36% and the worst being -21.1% [2]